ZNTL

#3326
Zentalis Pharmaceuticals, Inc. - common stock
4.1 1 USD
+0.09%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
4.11
4.11
Intervallo Annuale
1.21
6.95
Variazione giornaliera
+9.02%
Variazione Mensile
-16.29%
Variazione di 6 mesi
+66.40%
Variazione Annuale
+132.20%
Chiusura Precedente
3.7 7
Open
4.1 1
Minimo
4.1 1
Massimo
4.1 1
Volume
44
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K

Zentalis Pharmaceuticals, Inc. current report, Q1 FY2023

Full document

Business Context and Reporting Period

Zentalis Pharmaceuticals, Inc. (ZNTL) filed a Form 8-K on March 6, 2023, reporting the entry into a Material Definitive Agreement. The Company is a Delaware corporation with principal executive offices in New York, NY.

Key Financial Metrics

This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the terms of a new sublease agreement.

  • Sublease Term: Commences on the later of 10 business days after landlord consent or May 1, 2023, extending through November 29, 2032.
  • Base Rent (Years 1-5): Approximately $1.5 million per annum ($128,000 per month).
  • Base Rent (Year 6-End): Approximately $1.7 million per annum ($141,000 per month).
  • Rent Abatement: The agreement includes a 14-month rent abatement provision.

Material Changes

The Company entered into a Sublease Agreement with LM Cohen & Co. LLP for office space at 1359 Broadway, Suites 1710 and 1800, New York, NY. This space was originally leased by the Company under an agreement dated March 24, 2021. The filing notes that the Company's original lease obligations remain in full force and effect; the Sublease will terminate if the original Lease is terminated prior to November 29, 2032.

Guidance, Outlook, and Risks

The filing contains no financial guidance, management outlook, or discussion of general business risks. The primary contingency noted is that the Sublease is dependent on the continued existence of the original Lease with the Landlord (ESRT 1359 BROADWAY, L.L.C.).

Investor Verification Checklist

  • Verify the receipt of written consent from the Landlord to determine the exact commencement date of the Sublease.
  • Confirm the impact of the 14-month rent abatement on the Company's cash flow projections.
  • Review the original Lease Agreement (filed March 25, 2021) to understand the Company's remaining primary liability if the Subtenant defaults.
  • Assess whether the subletting of the premises aligns with the Company's current operational footprint and strategic plans.

Notizie